CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2015—Leica Biosystems has completed its acquisition of Devicor Medical Products. The Cincinnati-based company has annual revenues of approximately $170 million and more than 550 employees.
Devicor’s product portfolio includes the original Mammotome Breast Biopsy System, Mammotome Revolve, the tetherless Mammotome Elite, the Neoprobe Gamma Detection System, the Mammotome MammoTest stereotactic biopsy table, as well as a comprehensive portfolio of tissue markers used in breast disease diagnostic sampling and management.
Devicor will operate as a standalone business within Leica Biosystems.
Leica Biosystems, 800-248-0123